The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 601–700 of 1,006
Geyer, M. B., Shaffer, B. C., Bhatnagar, B., Mims, A. S., Klein, V., Dilip, D., Glass, J. L., Lozanski, G., Hassoun, H., Landau, H. J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009212 · Cited by 32
SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues
Carter, T. R., Milosevich, N., Dada, L., Shaum, J. B., Sharpless, K. B., Kitamura, S., & Erb, M. A. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117699 · Cited by 33
Immunomodulatory drugs in AL amyloidosis
Jelínek, T., Kufova, Z., & Hájek, R. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.004 · Cited by 33
Song, T., Liang, S., Liu, J., Zhang, T., Yin, Y., Geng, C., Gao, S., Feng, Y., Xu, H., Guo, D., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007165 · Cited by 31
Yang, Z., Wu, X., Wei, Y., Polyanskaya, S. A., Iyer, S. V., Jung, M., Lach, F. P., Adelman, E. R., Klingbeil, O., Milazzo, J. P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1542 · Cited by 33
St‐Cyr, D. J., Ceccarelli, D. F. J., Orlicky, S. M., van der Sloot, A. M., Tang, X., Kelso, S., Moore, S., James, C. A., Posternak, G., Coulombe‐Huntington, J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi5797 · Cited by 32
Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma
Cottini, F., Rodriguez, J., Hughes, T., Sharma, N., Guo, L., Lozanski, G., Liu, B., Cocucci, E., Yang, Y., & Benson, D. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0828 · Cited by 33
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Millrine, D., Miyata, H., Tei, M., Dubey, P. K., Nyati, K. K., Nakahama, T., Gemechu, Y., Ripley, B., & Kishimoto, T. (2016) · International Immunology · doi:10.1093/intimm/dxw005 · Cited by 33
Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms
Rodriguez-Rivera, F. P., & Levi, S. M. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00389 · Cited by 30
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 32
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity
Hu, J., Xu, H., Wu, T., Zhang, C., Shen, H., Dong, R., Hu, Q., Xiang, Q., Chai, S., Luo, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02195 · Cited by 30
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Lin, C. H.-T., Tariq, M. J., Ullah, F., Sannareddy, A., Khalid, F., Abbas, H., Bader, A., Samaras, C. J., Valent, J. N., Khouri, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116192 · Cited by 31
Feng, Y., Hu, X., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00638-1 · Cited by 30
Chen, Z., Dhruv, H., Zhang, X., Rej, R. K., Bai, L., McEachern, D., Kirchhoff, P. D., Nagilla, R., Jolivette, L. J., Rice, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58431-z · Cited by 30
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 31
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands
Boichenko, I., Deiss, S., Bär, K., Hartmann, M. D., & Alvarez, B. H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01735 · Cited by 31
Biology of CNS lymphoma and the potential of novel agents
Rubenstein, J. L. (2017) · Hematology · doi:10.1182/asheducation-2017.1.556 · Cited by 31
IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation
Li, S., Fu, J., Wang, H., Ma, H., Xu, X., Yang, Y.-G., Deng, S., Mapara, M. Y., & Lentzsch, S. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017010348 · Cited by 30
Dimopoulos, K., Munch‐Petersen, H. F., Eskelund, C. W., Sjø, L. D., Ralfkiaer, E. M., Gimsing, P., & Grønbæk, K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1466290 · Cited by 31
Immunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 33
Kim, M., Min, Y., Shim, J., Chun, E., & Lee, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02203 · Cited by 30
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
Nguyen, K. M., & Busino, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.007 · Cited by 30
Pharmacological targeting of natural killer cells for cancer immunotherapy
Miyazato, K., & Hayakawa, Y. (2020) · Cancer Science · doi:10.1111/cas.14418 · Cited by 34
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 30
Al‐Ghabkari, A., Huang, B., & Park, M. (2024) · Cells · doi:10.3390/cells13030218 · Cited by 31
Expanding role of lenalidomide in hematologic malignancies
Ghosh, N., Grunwald, M. R., Fasan, O. O., & Bhutani, M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s81310 · Cited by 31
Pomalidomide for multiple myeloma
Fouquet, G., Bories, C., Guidez, S., Renaud, L., Herbaux, C., Javed, S., Facon, T. T. F., & Leleu, X. P. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.966074 · Cited by 31
Targeted therapy for fusion-driven high-risk acute leukemia
Pikman, Y., & Stegmaier, K. (2018) · Blood · doi:10.1182/blood-2018-04-784157 · Cited by 30
Patil, A., Manzano, M., & Gottwein, E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019031732 · Cited by 29
Lin, J., Chen, Z., Zhang, D., Zhang, N., Chen, H., & Guo, D. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202401051 · Cited by 31
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 30
Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4
Ochiai, K., Yamaoka, M., Swaminathan, A., Shima, H., Hiura, H., Matsumoto, M., Kurotaki, D., Nakabayashi, J., Funayama, R., Nakayama, K., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108517 · Cited by 29
Zhao, M., Hu, M., Chen, Y., Liu, H., Chen, Y., Liu, B., & Fang, B. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.110 · Cited by 30
Hanel, W. G., & Epperla, N. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01113-2 · Cited by 29
Selective degradation-inducing probes for studying cereblon (CRBN) biology
Powell, C. E., Du, G., Bushman, J. W., He, Z., Zhang, T., Fischer, E. S., & Gray, N. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00382d · Cited by 30
Major, A., Kline, J. P., Karrison, T. G., Fishkin, P. A. S., Kimball, A. S., Petrich, A. M., Nattam, S. R., Rao, K., Sleckman, B. G., Cohen, K. S., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278853 · Cited by 29
Lin, S., Tu, G., Yu, Z., Jiang, Q., Zhang, L., Liu, J., Liu, Q., Huang, X., Xu, J., Lin, Y., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116912 · Cited by 30
Targeted protein degradation as an antiviral approach
Chakravarty, A., & Yang, P. L. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105480 · Cited by 29
Li, P., Hu, X., Fan, Z., Sun, S., Ran, Q., Wei, T., Wei, P., Jiang, Q., Yan, J. W., Yang, N., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01592-z · Cited by 30
Zhang, C., Li, X., Adelmant, G., Dobbins, J., Geisen, C., Oser, M. G., Wucherpfenning, K. W., Marto, J. A., & Kaelin, W. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522006112 · Cited by 31
Self-citationBhutani, M., Zhang, Q., Friend, R. N., Voorhees, P. M., Druhan, L. J., Barlogie, B., Sonneveld, P., Morgan, G. J., Symanowski, J. T., Avalos, B. R., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30143-6 · Cited by 29
Kikuchi, J., Kuroda, Y., Koyama, D., Osada, N., Izumi, T., Yasui, H., Kawase, T., Ichinohe, T., & Furukawa, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2446 · Cited by 30
Structural insights into DDA1 function as a core component of the CRL4-DDB1 ubiquitin ligase
Shabek, N., Ruble, J., Waston, C. J., Garbutt, K. C., Hinds, T. R., Li, T., & Zheng, N. (2018) · Cell Discovery · doi:10.1038/s41421-018-0064-8 · Cited by 31
The application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 31
Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex
Zhang, Z., Li, Y., Yang, J., Li, J., Lin, X., Liu, T., Yang, S., Lin, J., Xue, S., Yu, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50642-0 · Cited by 30
Hou, L., Zhao, J., Gao, S., Ji, T., Song, T., Li, Y., Wang, J., Geng, C., Long, M., Chen, J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau7130 · Cited by 28
Patel, V. G., & Cornell, R. F. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0784-4 · Cited by 30
Ubiquitin-dependent proteasomal degradation of AMPK gamma subunit by Cereblon inhibits AMPK activity
Yang, S., Jeon, S., Nguyen, T. V., Deshaies, R. J., Park, C., & Lee, K. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118729 · Cited by 29
Ye, Y., Gaudy, A. M., Schafer, P. H., Thomas, M. A., Weiss, D., Chen, N., Liu, L., Xue, Y., Carayannopoulos, L. N., & Palmisano, M. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.869 · Cited by 28
The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
Coll-Martínez, B., Delgado, A., & Crosas, B. (2020) · Molecules · doi:10.3390/molecules25245956 · Cited by 28
Jakobsen, T., Dahl, M., Dimopoulos, K., Grønbæk, K., Kjems, J., & Kristensen, L. S. (2021) · Cancers · doi:10.3390/cancers13030365 · Cited by 29
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 29
Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
Costacurta, M., He, J., Thompson, P. E., & Shortt, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111185 · Cited by 29
PSMA5 contributes to progression of lung adenocarcinoma in association with the JAK/STAT pathway
Lu, F., Zhou, J., Chen, Q., Zhu, J., Zheng, X., Fang, N., & Qiao, L. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac046 · Cited by 33
IKAROS: a multifunctional regulator of the polymerase II transcription cycle
Bottardi, S., Mavoungou, L. O., & Milot, É. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.05.003 · Cited by 29
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 30
Beedie, S., Huang, P. A., Harris, E. M., Strope, J. D., Mahony, C. B., Chau, C. H., Vargesson, N., & Figg, W. D. (2020) · The FASEB Journal · doi:10.1096/fj.201903060rr · Cited by 30
Chernobrovkin, A. L., Cázares-Körner, C., Friman, T., Caballero, I. M., Amadio, D., & Molina, D. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220984372 · Cited by 29
Mostofa, A., Distler, A., Meads, M. B., Sahakian, E., Powers, J. J., Achille, A., Noyes, D., Wright, G., Fang, B., Izumi, V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151713 · Cited by 27
Prodrug activation by 4,4’-bipyridine-mediated aromatic nitro reduction
Wang, Q., Song, Y., Yuan, S., Zhu, Y., Wang, W., & Chu, L. (2024) · Nature Communications · doi:10.1038/s41467-024-52604-y · Cited by 27
Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells
Hung, K.-H., Su, S.-T., Chen, C.-Y., Hsu, P.-H., Huang, S.-Y., Wu, W.-J. H., Chen, M.-J. M., Chen, H.-Y., Wu, P.-C., Lin, F.-R., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2015.167 · Cited by 34
Spironolactone‐induced XPB degradation depends on CDK7 kinase and SCFFBXL18 E3 ligase
Ueda, M., Matsuura, K., Kawai, H., Wakasugi, M., & Matsunaga, T. (2019) · Genes to Cells · doi:10.1111/gtc.12674 · Cited by 30
Tachita, T., Kinoshita, S., Ri, M., Aoki, S., Asano, A. T., Kanamori, T., Yoshida, T., Totani, H., Ito, A., Kusumoto, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14352 · Cited by 28
Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences
Venugopal, S., Mascarenhas, J. O., & Steensma, D. P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100735 · Cited by 27
The Role of Cullin-RING Ligases in Striated Muscle Development, Function, and Disease
Blondelle, J., Biju, A., & Lange, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217936 · Cited by 28
Recent advances in induced proximity modalities
Ng, C. S. C., & Banik, S. M. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102107 · Cited by 27
McCaughan, G. J. B., Gandolfi, S., Moore, J. J., & Richardson, P. G. G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18295 · Cited by 29
Protein ubiquitination in lymphoid malignancies
Yang, Y., & Staudt, L. M. (2014) · Immunological Reviews · doi:10.1111/imr.12247 · Cited by 29
Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention
Lee, D. H., & Fradley, M. G. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0618-y · Cited by 27
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 28
Eichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 32
Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy
Young, R. M., Phelan, J. D., Shaffer, A. L., Wright, G. W., Huang, D. W., Schmitz, R., Johnson, C. A., Oellerich, T., Wilson, W. H., & Staudt, L. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055734 · Cited by 31
Lü, J., Jiang, H., Li, D., Chen, T., Wang, Y., Pu, Z., & Xu, G. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00437 · Cited by 27
Advances in the Design and Development of PROTAC-mediated HDAC Degradation
Rodrigues, D. A., Roe, A. J., Griffith, D. M., & Chonghaile, T. N. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211015092047 · Cited by 28
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
Vicente, A. T. S., Moura, S. P. S. P., & Salvador, J. A. R. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01598-9 · Cited by 29
How multispecific molecules are transforming pharmacotherapy
Deshaies, R. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01262-w · Cited by 29
Immunoproteasome Function in Normal and Malignant Hematopoiesis
Santamaría, N. T., Ebstein, F., Heidel, F. H., & Krüger, E. (2021) · Cells · doi:10.3390/cells10071577 · Cited by 30
Uehling, D., Joseph, B., Chung, K. C., Zhang, A. X., Ler, S., Prakesch, M. A., Poda, G. I., Grouleff, J., Aman, A. M., Kiyota, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00506 · Cited by 30
Jones, J. R., Barber, A., Bihan, Y. L., Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Wang, H., Kaiser, M., Jackson, G. H., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01373-4 · Cited by 29
Takwale, A. D., Kim, E. Y., Jang, Y., Lee, D.-H., Kim, S., Choi, Y., Kim, J. H., Lee, D. Y., Kim, Y., Lee, S. M., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105923 · Cited by 27
A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
Kopp, K. O., Greer, M. E., Glotfelty, E. J., Hsueh, S., Tweedie, D., Kim, D. S., Reale, M., Vargesson, N., & Greig, N. H. (2023) · Biomolecules · doi:10.3390/biom13050747 · Cited by 26
Zhou, B., Li, H., Xing, C., Ye, H., Feng, J., Wu, J., Lu, Z., Fang, J., & Gao, S. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.022 · Cited by 26
Scott, G. B., Carter, C. R. D., Parrish, C., Wood, P. M. D., & Cook, G. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.05.002 · Cited by 26
Liu, A., Li, S., Donnenberg, V. S., Fu, J., Gollin, S. M., Ma, H., Lu, C., Stolz, D. B., Mapara, M. Y., Monaghan, S. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188227 · Cited by 26
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases
Blaquière, N., Villemure, E., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01451 · Cited by 26
Perner, F., & Armstrong, S. A. (2020) · Cells · doi:10.3390/cells9122721 · Cited by 26
Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
Wirsching, H., Weller, M., Balabanov, S., & Roth, P. (2021) · Cancers · doi:10.3390/cancers13123073 · Cited by 27
Degradome analysis to identify direct protein substrates of small-molecule degraders
Jochem, M., Schrempf, A., Wagner, L.-M., Segal, D., Cisneros, J., Ng, A., Winter, G. E., & Krijgsveld, J. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.007 · Cited by 25
Recent advances in dual PROTACs degrader strategies for disease treatment
Liu, J., Liu, Y., Tang, J., Gong, Q., Yan, G., Fan, H., Zhang, X., & Pu, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116901 · Cited by 25
Zhou, Y., Garrigues, S. L., Villemure, E., Ishisoko, N., Nguyen, H. Q., Hamidi, N. K., Vogt, R., Wang, Y., Blake, R. A., Rudolph, J., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00445 · Cited by 27
Fu, S.-J., Hu, M., Peng, Y.-J., Fang, H.-Y., Hsiao, C.-T., Chen, T., Jeng, C., & Tang, C. (2020) · Cells · doi:10.3390/cells9061332 · Cited by 25
Rivellese, F., Manou-Stathopoulou, S., Mauro, D., Goldmann, K., Pyne, D., Rajakariar, R., Gordon, P., Schafer, P. H., Bombardieri, M., Pitzalis, C., et al. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000445 · Cited by 25
CD4 + T cells require Ikaros to inhibit their differentiation toward a pathogenic cell fate
Bernardi, C., Maurer, G., Ye, T., Marchal, P., Jost, B., Wissler, M., Maurer, U., Kastner, P., Chan, S. H., & Charvet, C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023172118 · Cited by 26
Epstein–Barr Virus B Cell Growth Transformation: The Nuclear Events
Zhao, B. (2023) · Viruses · doi:10.3390/v15040832 · Cited by 26
Targeting phosphatases: From molecule design to clinical trials
Guo, M., Li, Z., Gu, M., Gu, J., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116031 · Cited by 26
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 27
Blaes, A. H., Thavendiranathan, P., & Moslehi, J. J. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_208509 · Cited by 27
de Jonge, A. V., Mutis, T., Roemer, M. G. M., Scheijen, B., & Chamuleau, M. E. D. (2020) · Cancers · doi:10.3390/cancers12103052 · Cited by 26
Tong, K. I., Yoon, S., Isaev, K., Bakhtiari, M., Lackraj, T., He, M. Y., Joynt, J., Silva, A., Xu, M. C., Privé, G. G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4027 · Cited by 26
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.